Nasdaq:US$13.50 (+0.55) | HKEX:HK$21.80 (+0.60) | AIM:£2.26 (+0.09)
Search
Announcements
12345678
9
10111213
found Documents: 650
Announcements & Press Releases, Group | 1 Mar 2016

Fourth Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
Read More
View Full Announcement (PDF)
Announcements & Press Releases, Group | 1 Mar 2016

Final Results for the year ended 31 December 2015
Record profit from operations at both Group and Commercial Platform levels Excellent progress on all lead drug candidates – five out of five positive Phase Ib/II outcomes in 2015 Seven drug candidates – 19 active clinical trials – 3 Phase III
Read More
View Full Announcement (PDF)View Announcement Summary (PDF)View Chairman's Statement (PDF)View Operations Review (PDF)View Financial Statements (PDF)
Announcements & Press Releases, Group | 11 Feb 2016

Third Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 29 Jan 2016

Notice of Announcement of 2015 Final Results
London: Friday, 29 January 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) will be announcing its final results for the year ended 31 December 2015 on Tuesday, 1 March 2016.  An analyst presentation will be held at 9:00 am on the
Read More
Announcements & Press Releases, Oncology / Immunology, Press Releases | 15 Jan 2016

Initiation of HMPL-523 Phase I clinical trial in haematological cancer in Australia
London: Friday, 15 January 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated a Phase I trial in Australia in patients with haema
Read More
View PDF
Announcements & Press Releases, Regulatory Notice | 29 Dec 2015

Blocklisting Six Monthly Return
London: Tuesday, 29 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces the following blocklisting six monthly return:   1. Name of applicant: Hutchison China MediTech Limited   2. Name of scheme: Hutc
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 18 Dec 2015

Initiation of sulfatinib Phase III registration study in neuroendocrine tumour patients
London: Friday, 18 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) regist
Read More
View Announcement (PDF)
Announcements & Press Releases, Other Ventures, Press Releases | 9 Dec 2015

US$105 million Shanghai land compensation agreement
Press Release London: Wednesday, 9 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited (“SHPL”), its 50:50 joint venture with a subsidiary of Shanghai Pharma
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 8 Dec 2015

Initiation of fruquintinib Phase III registration trial in non-small cell lung cancer
London: Tuesday, 8 December 2015: Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated FALUCA, a Phase III registration study for fruqu
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 13 Nov 2015

Second Public Filing of Registration Statement on Form F‑1 for potential Nasdaq Stock Market Listing
The following includes the text of the Announcement, excluding the appendix. For the complete Announcement, please download the PDF. --- NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEM
Read More
View Full Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 10 Nov 2015

Results of Extraordinary General Meeting
London: Tuesday, 10 November 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that the ordinary resolution and the special resolution put to its Extraordinary General Meeting held on 10 November 2015 (“EGM”) were
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 9 Nov 2015

Director's Share Dealing
London: Monday, 9 November 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) hereby makes the following amendments to the "Director's Share Dealing" announcement released on 20 October 2015 subsequent to the notification received from Mr
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 6 Nov 2015

Chi-Med initiates sulfatinib U.S. clinical trials
London: Friday, 6 November 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated the Phase I clinical trial of sulfatinib (HMPL-012
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 30 Oct 2015

Sulfatinib clinical results and fruquintinib-savolitinib combination preclinical results to be presented at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference
 Press Release London: Friday, 30 October 2015: Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, will present further scientific data on sulfa
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Oct 2015

Total Voting Rights
London: Friday, 30 October 2015: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) hereby notifies the market that as at 30 October 2015, the issued share capital of Chi-Med consisted of 56,533,118 ordinary shares
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 30 Oct 2015

Completion of Phase I clinical trial of novel Syk Inhibitor HMPL-523 for autoimmune diseases in healthy volunteers
London:  Friday, 30 October 2015:  Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has successfully completed its first-in-human Phase I clini
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 23 Oct 2015

Proof-of-concept study of fruquintinib in non-small cell lung cancer triggers milestone payment
London: Friday, 23 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, is set to receive a US$10 million milestone payment, in the fourt
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 20 Oct 2015

Director's Share Dealing
London: Tuesday, 20 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) received notification on 19 October 2015 that Mr Christopher Nash, Independent Non-executive Director, has: purchased jointly with his spouse 4,512 ordi
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 19 Oct 2015

Awards under Long Term Incentive Plan
London: Monday, 19 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that the Remuneration Committee of Chi-Med today granted conditional awards (the “LTIP Awards”) under the Long Term Incentive Plan (the “LTIP
Read More
View Announcement (PDF)
Announcements & Press Releases, Group, Press Releases | 16 Oct 2015

Hutchison China MediTech Limited Files Registration Statement for Potential Nasdaq Stock Market Listing
Press Release London: Friday, 16 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that it has publicly filed today a registration statement on Form F-1 (the "Registration Statement") with the United States Securiti
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 16 Oct 2015

Shareholders' Circular and Notice of Extraordinary General Meeting
London: Friday, 16 October 2015: Hutchison China MediTech Limited ("Chi-Med”) (AIM: HCM) today announces that, following the announcement that it had publicly filed a registration statement on Form F-1 ("Form F-1 Registration Statement") with the U
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 16 Oct 2015

Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing
The following includes the text of the Announcement but excludes the appendix. For the complete release, please download the PDF. --- NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEM
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 13 Oct 2015

Savolitinib completes enrolment for Phase II clinical trial in Papillary Renal Cell Carcinoma
Press Release London: Tuesday, 13 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, and AstraZeneca AB (publ) (“AstraZeneca”) ha
Read More
View PDF
Announcements & Press Releases, Regulatory Notice | 12 Oct 2015

Holding(s) in Company
For filings with the FCA include the annex   For filings with issuer exclude the annex     TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi     1. Identity of the issuer or t
Read More
Download PDF
Announcements & Press Releases, Group | 8 Oct 2015

Winner of International Company of the Year 2015, AIM
At the 2015 AIM Awards, Chi-Med was awarded the title of International Company of the Year. The AIM Awards look at how companies and individuals harness AIM to power their growth and fulfil their strategy. The AIM Awards scrutinises recent joiners
Read More
Announcements & Press Releases, Oncology / Immunology | 14 Sep 2015

Fruquintinib Phase II clinical results in colorectal cancer to be presented at the 2015 European Cancer Congress
London: Monday, 14 September 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, will present the detailed clinical results of its Phase II proo
Read More
View PDF
Announcements & Press Releases, Oncology / Immunology | 2 Sep 2015

Second proof-of-concept trial of fruquintinib achieves its primary endpoint
London: Wednesday, 2 September 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, successfully achieved the primary endpoint in the second proo
Read More
View PDF
Announcements & Press Releases, Oncology / Immunology | 19 Aug 2015

Termination of Research & Development Alliance Agreement with Janssen Relating to HMPL-507 Project
London: Wednesday, 19 August 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that, Hutchison MediPharma Limited (“HMP”), its R&D subsidiary, has received notice from Janssen Pharmaceutical, Inc. (Janssen) of
Read More
View PDF
Announcements & Press Releases, Group | 28 Jul 2015

Interim Results for the Six Months Ended 30 June 2015
For the complete release, please download the PDF. --- Drug R&D Division - our Innovation Platform: enrolling 17 clinical trials (H1 2014: 10), with 24 targeted by year-end. China Healthcare and Consumer Products Divisions - our Commercial
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 23 Jul 2015

TR-1: Notification of major interest in shares
View PDF
Announcements & Press Releases, Regulatory Notice | 23 Jul 2015

TR-1: Notification of major interest in shares
PDF
Announcements & Press Releases, Oncology / Immunology | 23 Jul 2015

Mitsui exchanges its shares in Hutchison MediPharma for shares in Chi-Med
London: Thursday, 23 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that it has signed a subscription agreement (the "Agreement") and completed the exchange of 5,247,493 convertible preference shares held by Mitsui
Read More
PDF
Announcements & Press Releases, Other Ventures | 17 Jul 2015

20-year invention patent granted on Chi-Med's best selling prescription drug
London: Friday, 17 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited ("SHPL"), its prescription drug joint venture, has been granted an invention patent in China ("Inven
Read More
a150717
Announcements & Press Releases, Regulatory Notice | 6 Jul 2015

Notice of Announcement of 2015 Interim Results
London: Monday, 6 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) will be announcing its interim results for the six months ended 30 June 2015 on Tuesday, 28 July 2015. An analyst presentation will be held at 9:00 am on the same d
Read More
a150706
Announcements & Press Releases, Regulatory Notice | 29 Jun 2015

Blocklisting Six Monthly Return
London: Monday, 29 June 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM)announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of
Read More
a150629
Announcements & Press Releases, Oncology / Immunology | 1 Jun 2015

Savolitinib (AZD6094) preliminary Phase Ib clinical data in lung cancer presented at the 2015 ASCO Annual Meeting
London: Monday, 1 June 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM), today announces that AstraZeneca AB (publ) (“AstraZeneca”), Hutchison MediPharma Limited’s (“HMP”) collaboration partner, presented preliminary data f
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 13 May 2015

Positive fruquintinib proof-of-concept study results trigger payments from Lilly
London: Wednesday, 13 May 2015: Chi-Med today announces that Hutchison MediPharma Limited (“HMP”), its majority owned drug R&D company, is set to receive a total of US$18 million in payments, in the second quarter of 2015, from Eli Lilly and
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Apr 2015

Total Voting Rights
London: Thursday, 30 April 2015: For information purposes, Chi-Med hereby notifies the market that as at 30 April 2015, the issued share capital of Chi-Med consisted of 53,299,964 ordinary shares of US$1.00 each, with each share carrying one right to
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 24 Apr 2015

Results of Annual General Meeting
London: Friday, 24 April 2015: Chi-Med today announces that all ordinary resolutions and special resolution put to its Annual General Meeting ("AGM") held on 24 April 2015 were duly passed. Please download the PDF.  
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 22 Apr 2015

Director's Shareholding
London: Wednesday, 22 April 2015: Chi-Med received notification on 22 April 2015 that Mr Christopher Nash, Independent Non-executive Director, has purchased 1,388 ordinary shares of US$1.00 each in Chi-Med (the “Shares”) at a price of GBP18.00 pe
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 16 Apr 2015

Director's Shareholding
London: Thursday, 16 April 2015: Chi-Med received notification on 16 April 2015 that Simon To, Executive Director and Chairman, has purchased 28,000 ordinary shares of US$1.00 each in Chi-Med (the “Shares”) at a price of GBP15.85 per share on 15
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 13 Apr 2015

Director's Shareholding
London: Monday, 13 April 2015: Chi-Med received notification on 13 April 2015 that Simon To, Executive Director and Chairman, has purchased 25,000 ordinary shares of US$1.00 each in Chi-Med (the “Shares”) at a price of GBP14.215 per share on 10 A
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 8 Apr 2015

Directors' Shareholding
London: Wednesday, 8 April 2015: Chi-Med received notifications on 8 April 2015 that the following Directors have purchased ordinary shares of US$1.00 each in Chi-Med (the "Shares") as follows:- Director Date of purchase
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Apr 2015

Directors' Shareholding
London: Wednesday, 1 April 2015: Chi-Med received notifications on 1 April 2015 that the following Directors have purchased ordinary shares of US$1.00 each in Chi-Med (the "Shares") as follows:- Director Date of purchase Numbe
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Apr 2015

Exercise of Options
London: Wednesday, 1 April 2015: Chi-Med announces that it has issued 64,038 ordinary shares of US$1.00 each (the "Shares") following the exercise of options by Mr Johnny Cheng, Executive Director and Chief Financial Officer of Chi-Med, at an exercis
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 30 Mar 2015

The first proof-of-concept trial of fruquintinib achieves primary efficacy endpoint
London: Monday, 30 March 2015: Chi-Med, today announces that Hutchison MediPharma Limited ("HMP"), its majority owned drug R&D company, successfully achieved the primary endpoint in the first proof-of-concept ("POC") trial of fruquintinib in pati
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 23 Mar 2015

2014 Annual Report and Notice of Annual General Meeting
London: Monday, 23 March 2015: Chi-Med today announces that its 2014 Annual Report together with the Notice of Annual General Meeting and the Proxy Form have been posted to shareholders. The documents can be accessed from the website of Chi-Med (www.
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 18 Mar 2015

TR-1: Notification of major interest in shares
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 6 Mar 2015

Patient enrolment completion for fruquintinib's Phase II study in non-small cell lung cancer; Fruquintinib development moving rapidly in four parallel studies in non-small cell lung cancer, colorectal cancer and gastric cancer
London: Friday, 6 March 2015: Chi-Med, today announces that Hutchison MediPharma Limited ("HMP"), its majority owned drug R&D company, has completed patient enrolment in a Phase II clinical trial of fruquintinib (HMPL-013) in non-small cell lung
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 26 Feb 2015

Final Results for the year ended 31 December 2014
For the complete release, please download the PDF. -- Break-out year for Drug R&D Division with 16 clinical studies on 7 drug candidates; 10 potential Breakthrough Therapy indications; as well as record China Healthcare Division revenues and
Read More
View Announcement (PDF)
12345678
9
10111213